Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, Feb. 21 '26)

Image
By G.M.

 


    Antiviral Res

  1. WRONSKI S, Obernolte H, Schaudien D, Braun A, et al
    Prophylactic intranasal administration of bacterial lysate OM-85 mitigates human rhinovirus (RV-A1b) lung infection and inflammation in mice.
    Antiviral Res. 2026;247:106362.
    PubMed         Abstract available

  2. HEDSKOG C, Rodriguez L, Hu Y, Li J, et al
    SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.
    Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351.
    PubMed         Abstract available

  3. RODRIGUEZ L, Hu Y, Li J, Han D, et al
    SARS-CoV-2 Resistance Analyses From the Phase 3 OAKTREE Study of Obeldesivir in Low-Risk Nonhospitalized Participants With COVID-19.
    Antiviral Res. 2025 Dec 29:106339. doi: 10.1016/j.antiviral.2025.106339.
    PubMed         Abstract available


    Arch Virol

  4. LIM KS, Selvan ME, Ea CK, Teo CH, et al
    CircRNA expression profiling in H1N1-infected primary human tracheobronchial epithelial cells identifies candidate immune-related circRNAs validated in A549 cells.
    Arch Virol. 2026;171:85.
    PubMed         Abstract available

  5. JAMAL Z, Haider SA, Humayun F, Ali Q, et al
    Genomic surveillance of Influenza, SARS-CoV-2, and RSV in patients from Islamabad and Rawalpindi, Pakistan: a 2023-24 perspective.
    Arch Virol. 2026;171:78.
    PubMed        

  6. SHILOVA NV, Yermolaeva DR, Nokel AY, Chinarev AA, et al
    Antibody-free detection of influenza viruses on a microarray to study their receptor specificity.
    Arch Virol. 2026;171:75.
    PubMed        


    Epidemiol Infect

  7. MARQUEZ J, Garcia-Garcia D, Vigo MI, Bordehore C, et al
    Retrospective estimate of COVID-19 infections in nine Colombian cities in 2020.
    Epidemiol Infect. 2026;154:e22.
    PubMed         Abstract available


    J Gen Virol

  8. PAN X, Shi X, Zhao L, Yan D, et al
    Amino acid mutations K54E and S154P in the neuraminidase attenuate H3N2 canine influenza virus in mice.
    J Gen Virol. 2026;107.
    PubMed         Abstract available


    J Infect

  9. LIU K, Wang X, Huang J, Liu P, et al
    Zoonotic Threat of Novel H6N2 Avian Influenza Virus with Internal Genes Exclusively Derived from H9N2, China, 2025.
    J Infect. 2026 Feb 18:106705. doi: 10.1016/j.jinf.2026.106705.
    PubMed        


    J Infect Dis

  10. CHAPPELL KJ, Mordant FL, Amarilla AA, Modhiran N, et al
    Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial.
    J Infect Dis. 2025 Nov 25:jiaf568. doi: 10.1093.
    PubMed         Abstract available

  11. IGLESIAS-CABALLERO M, Mas V, Campoy A, Calvo C, et al
    Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.
    J Infect Dis. 2026;233:e409-e418.
    PubMed         Abstract available

  12. HOFSINK Q, Lissenberg-Witte BI, Haggenburg S, Goorhuis A, et al
    COVID-19 Vaccine Effectiveness in Patients with Hematologic Malignancies: a Nationwide Cohort Study.
    J Infect Dis. 2025 Oct 14:jiaf523. doi: 10.1093.
    PubMed         Abstract available

  13. EDWARDS DL, Feldstein LR, Dalton AF, Ford ND, et al
    Prevalence of Symptoms Associated With Long COVID Among Adolescents in the United States, Summer 2022.
    J Infect Dis. 2026;233:e352-e362.
    PubMed         Abstract available

  14. LI B, Ke Y, Chen X, Martinez L, et al
    Robust COVID-19 Mortality Risk Assessment: Validation of a Two-Step Algorithm From the National COVID Cohort Collaborative.
    J Infect Dis. 2026;233:351-362.
    PubMed         Abstract available

  15. OKABE H, Hashimoto K, Norito S, Ono T, et al
    Respiratory Syncytial Virus Fusion Protein Epitope-Specific Antibodies and Neutralizing Activities Against Various Respiratory Syncytial Virus Strains.
    J Infect Dis. 2026;233:334-341.
    PubMed         Abstract available


    J Virol

  16. HAZELL NC, Reyna RA, Adam A, Bonam SR, et al
    mRNA-delivered neutralizing antibodies confer protection against SARS-CoV-2 in animal models.
    J Virol. 2026 Jan 7:e0189725. doi: 10.1128/jvi.01897.
    PubMed         Abstract available

  17. MASTERS PS
    Coronavirus genome packaging and nucleocapsid assembly.
    J Virol. 2026 Jan 8:e0133025. doi: 10.1128/jvi.01330.
    PubMed         Abstract available

  18. ALVARADO RE, Lokugamage KG, Garvanska D, Estes LK, et al
    Key residues in SARS-CoV-2 NSP3 hypervariable region are necessary to modulate early stress granule activity.
    J Virol. 2026 Jan 14:e0200625. doi: 10.1128/jvi.02006.
    PubMed         Abstract available

  19. TIEN C-F, Lin E-J, Tsai W-H, Tsai W-T, et al
    SARS-CoV-2 spike protein expression drives post-acute coagulopathy.
    J Virol. 2026 Jan 21:e0125525. doi: 10.1128/jvi.01255.
    PubMed         Abstract available

  20. NAKANO T, Esaki M, Inoue A, Koike F, et al
    Impact of an amino acid deletion detected in the hemagglutinin (HA) antigenic site of swine influenza A virus field strains on HA antigenicity.
    J Virol. 2026 Feb 19:e0182025. doi: 10.1128/jvi.01820.
    PubMed         Abstract available


    JAMA

  21. DILEK S, Rosen J, Levashkevich A, Sharfstein JM, et al
    The US Food and Drug Administration's Regulation of Mifepristone.
    JAMA. 2026 Jan 12. doi: 10.1001/jama.2025.23091.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  22. SILK BJ, Prill MM, Winn AK, Patton ME, et al
    Respiratory Virus Activity - United States, July 1, 2024-June 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:77-84.
    PubMed         Abstract available

  23. RAYKIN J, Rochin I, Wiegand R, Soto V, et al
    COVID-19 Antiviral Prescription Receipt Among Outpatients Aged >/=65 Years - United States, June 1, 2023-September 30, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:69-76.
    PubMed         Abstract available


    N Engl J Med

  24. RASMUSSEN SA, Jernigan DB
    Antigenic Drift and Antivaccine Shift in the 2025-2026 Influenza Season.
    N Engl J Med. 2026;394:732-735.
    PubMed        


    PLoS One

  25. ROONEY G, Loibl C
    Scarcity mindset's positive association with using alternative financial services.
    PLoS One. 2026;21:e0339127.
    PubMed         Abstract available

  26. KAKKAR M, Sharma D, Pal M, Mohapatra A, et al
    An analysis of WHO FluNet and FluID influenza surveillance data for South East Asia Region, 2015-2023.
    PLoS One. 2026;21:e0341567.
    PubMed         Abstract available

  27. CHAKRABORTY A, Diwan A, Chiniga V, Arora V, et al
    Remdesivir-bisPropionate, a better derivative of remdesivir against SARS-CoV-2: Comparison of in vitro and in vivo PK/PD Study as well as its therapeutic potential.
    PLoS One. 2026;21:e0324811.
    PubMed         Abstract available

  28. THAKUR A, Meza-Torres B, Fan X, Byford R, et al
    Prediction of COVID-19 hospitalisation, ICU admission or death following ChAdOx1 vaccination using artificial intelligence: A clinical predictive model from the English RAVEN study.
    PLoS One. 2026;21:e0336449.
    PubMed         Abstract available

  29. LI J, Xie Z, Chen Y, Jin G, et al
    Trends and associations of pulmonary nodule detection rates in China, 2019-2023: A multicenter cross-sectional study based on Real-World Data.
    PLoS One. 2026;21:e0343207.
    PubMed         Abstract available

  30. ROBERTSON LS
    Prayer, politics, and policy related to age-adjusted cancer, heart disease, infant mortality, and COVID-19 death Rates, U.S. states 2018-2021.
    PLoS One. 2026;21:e0343211.
    PubMed         Abstract available

  31. WILLANE CT, Sylla PMDD, Thiam M, Ndiaye BM, et al
    Optimizing nutritionally adequate food basket using linear programming in Niayes Households, Senegal.
    PLoS One. 2026;21:e0343156.
    PubMed         Abstract available

  32. KHEZRIMOTLAGH D, Imanpour S, Akbas E
    Reassessing the emergency department burden of influenza: A comprehensive real-world analysis using administrative data.
    PLoS One. 2026;21:e0340699.
    PubMed         Abstract available

  33. CARTWRIGHT T, Metcalf L, Wadhen V
    'It is a lifeline': International cross-sectional survey of benefits, barriers and acceptability of online yoga during the COVID-19 pandemic.
    PLoS One. 2026;21:e0341852.
    PubMed         Abstract available

  34. DIDRIKSSON I, Toniste D, Hultgren M, Spangfors M, et al
    Three-year functional, physical, and mental health outcomes after critical COVID-19: A prospective multicentre cohort study.
    PLoS One. 2026;21:e0341319.
    PubMed         Abstract available

  35. LEONTI M, Mollica C, Spadaccini S, Casu L, et al
    Treatments for COVID-19 and acute respiratory infections are associated with gender and comorbidities in an Italian online survey.
    PLoS One. 2026;21:e0342466.
    PubMed         Abstract available

  36. MCMASTER JMV, Gellersen HM, Korkki SM, Simons JS, et al
    The impact of lifestyle restrictions on memory in older adults.
    PLoS One. 2026;21:e0342458.
    PubMed         Abstract available

  37. MARTINEZ-BORBA V, Rodriguez-Marquez AE, Garces-Arilla S, Peris-Baquero O, et al
    Effectiveness and acceptability of the unified protocol for the transdiagnostic treatment of emotional disorders in people with long COVID-19: Study protocol for a randomized controlled trial.
    PLoS One. 2026;21:e0342908.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  38. LIU C, Zheng J, Wang Y, Beck F, et al
    Cryo-EM structure of locked spike glycoprotein from bat SARS-like coronavirus WIV1, molecular dynamics and biophysics across host range.
    Proc Natl Acad Sci U S A. 2026;123:e2516874123.
    PubMed         Abstract available


    Vaccine

  39. SOBLE A, Koh M, Taaffe J, Procter SR, et al
    Evaluating the broader impact of improved influenza vaccines: A full value of vaccine assessment approach.
    Vaccine. 2026;60 Suppl 2:128166.
    PubMed         Abstract available

  40. CONTARINO F, Fiorilla C, Bella F, Leonforte F, et al
    Missed opportunities and co-administration patterns for influenza vaccination in older adults in Italy: a retrospective cohort study.
    Vaccine. 2026;77:128366.
    PubMed         Abstract available

  41. GREEN MA, Jeffery C, Cheyne C, Bonnett L, et al
    Learning from the outliers: A longitudinal ecological study of social and spatial inequalities in older adult influenza vaccination and hospitalisation (Cheshire and Merseyside, UK, 2018-19 to 2023-24).
    Vaccine. 2026;77:128356.
    PubMed         Abstract available

  42. ANDERSON SA, Smith ER, Wan Z, Amend KL, et al
    Febrile seizure risk following monovalent COVID-19 mRNA vaccination in US children aged 2-5 years.
    Vaccine. 2026;75:128225.
    PubMed         Abstract available

  43. SHARMA AJ, Smoots AN, Madni SA, Zauche LH, et al
    COVID-19 vaccination during or just prior to pregnancy and hypertensive disorders of pregnancy.
    Vaccine. 2026;75:128268.
    PubMed         Abstract available

  44. TONDEL C, Jenum S, Tonby K, Christensen EE, et al
    SARS-CoV-2T-cell vaccine VB10.2210 induces broad T-cell responses in a phase 1/2 open-label clinical trial.
    Vaccine. 2026;75:128290.
    PubMed         Abstract available

  45. KENEALY T, Aguirre-Duarte N, Roxburgh RH, Royle G, et al
    Accuracy of ICD and SNOMED search strategies for adverse events following COVID-19 vaccination: Analysis of hospital administrative data.
    Vaccine. 2026;75:128275.
    PubMed         Abstract available

  46. PARK IY, Cantu-Aldana A, Grafft N, Lo BK, et al
    Fathers' reports of within-household vaccine decision making and young children's COVID-19 vaccination status.
    Vaccine. 2026;75:128282.
    PubMed         Abstract available

  47. THAKKAR K, Kefalogianni R, Zhang J, Yung CF, et al
    Clinical and economic benefits of bivalent respiratory syncytial virus prefusion F (RSVpreF) maternal vaccine for prevention of RSV illness in infants: A cost-effectiveness analysis for Singapore.
    Vaccine. 2026;75:128285.
    PubMed         Abstract available

  48. LOTSPEICH-COLE L, Jha MK, Parvathaneni S, Lee RC, et al
    Neonatal mice immune response to COVID-19 mRNA vaccine.
    Vaccine. 2026;75:128271.
    PubMed         Abstract available

  49. HAHM HC, Tang M, Lupaczyk L, Lee J, et al
    Beyond the shot: A framework of individual and external influences on U.S. young adults' COVID-19 vaccination decisions derived from thematic analysis.
    Vaccine. 2026;75:128283.
    PubMed         Abstract available

  50. BARBER C, Barber M, Lee JSW, Ting J, et al
    Vaccination policies, practices, and procedures in level-III neonatal intensive care units across Canada: An environmental scan.
    Vaccine. 2026;75:128261.
    PubMed         Abstract available

  51. VATTOTH AL, Hayney MS, Forati AM, Warren B, et al
    Immunogenicity and safety of a recombinant spike protein COVID vaccine in patients with inflammatory bowel disease and transplant recipient.
    Vaccine. 2026;75:128208.
    PubMed         Abstract available

  52. YESENIA RODRIGUEZ-TANTA L, Delgado-Escalante R, Del Pilar Solis-Yucra T, Rojas EC, et al
    Post-marketing safety surveillance of the BBIBP-CorV (Sinopharm) COVID-19 vaccine in Peruvian healthcare workers: A retrospective analysis of a Pharmacovigilance Center.
    Vaccine. 2026;75:128227.
    PubMed         Abstract available

  53. YIGIT I, Stoner MCD, Muessig KE, Hightow-Weidman LB, et al
    Pathways to COVID-19 vaccine initiation: The roles of medical mistrust, conspiracy beliefs, hesitancy, and confidence among black young adults.
    Vaccine. 2026;75:128253.
    PubMed         Abstract available

  54. HANDY AB, Ren B, Seidman LC, Granger SW, et al
    Inflammatory mechanisms of menstrual cycle changes following COVID-19 vaccination in adolescents.
    Vaccine. 2026;75:128226.
    PubMed         Abstract available

  55. FAIJUE DD, Bouaddi O, Mackey K, Deal A, et al
    Strategies, interventions, and uptake of catch-up vaccination among adolescent and adult migrants, refugees, and internally displaced persons (IDPs) in low- and middle-income countries (LMICs): A systematic review.
    Vaccine. 2026;75:128249.
    PubMed         Abstract available

  56. MALTEZOU HC, Giannouchos TV, Gamaletsou MN, Koukou DM, et al
    Absenteeism related to respiratory infections among healthcare personnel in hospitals in Greece from 2020-2021 to 2024-2025.
    Vaccine. 2026;75:128264.
    PubMed         Abstract available

  57. ADAM A, Lee C, Jones MC, Harrington BR, et al
    VSA-2-, a novel plant-derived adjuvant for SARS-CoV-2 subunit vaccine.
    Vaccine. 2026;75:128255.
    PubMed         Abstract available

  58. OKOLI GN, Kwan MYW, Chan ELY, Murphy C, et al
    Estimates of SARS-CoV-2 vaccine effectiveness against COVID-19-associated hospitalisation in paediatric patients in Hong Kong during two successive SARS-CoV-2 epidemic waves dominated by the Omicron variant: A test-negative design study.
    Vaccine. 2026;75:128262.
    PubMed         Abstract available

  59. MANSFIELD ME, Okui L, Simon S, Hosangadi D, et al
    Understanding COVID-19 vaccination choices and development of a toolkit and training for Botswana, 2022-2023.
    Vaccine. 2026;75:128274.
    PubMed         Abstract available

  60. PAXITZIS AN, Oyebanji OA, Olagunju OJ, Keresztesy D, et al
    Antibody responses to SARS-CoV-2 vaccine in nursing home residents support a Bi-annual update schedule.
    Vaccine. 2026;75:128240.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »